V8 Peptides — Engineered Performance
Research Library
CJC-1295 + Ipamorelin Research Stack: Evidence Map
CJC-1295 & IpamorelinStacks

CJC-1295 + Ipamorelin Research Stack: Evidence Map

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What does the evidence for a CJC-1295 + ipamorelin research stack actually consist of? Two separate bodies of work: the GHRH-analog literature (receptor, plasma persistence, a knockout-mouse growth study, mostly on the albumin-binding form) and the ipamorelin literature (selective GH release in rat cells, rats and swine). Their combination in one design is a reasoned inference from two receptors on one cell type, not a result established by a dedicated primary study in the references here. This article maps each common claim to its source or marks it as inference. For laboratory research use only.

“Research stack” is a catalog phrase. It tells a reader that two compounds are often studied together; it does not say what has been shown. For anyone planning a study, the useful question is which statements about the pair are documented, which are extrapolations and which are open. The sections below take the claims one at a time. For product and handling detail, see the blend page; for how the stack relates to its parts, see the CJC-1295 and ipamorelin research overview. For laboratory research use only; not for human consumption.

The map

ClaimSupportSource in this articleStatus
A pituitary GHRH receptor exists and signals through cAMPCloning and binding dataMayo, 1992Established
A distinct receptor in pituitary and hypothalamus mediates GH release by secretagoguesReceptor identificationHoward and colleagues, 1996Established
Ghrelin is the endogenous ligand of that receptorPeptide isolated from stomach as GH-releasingKojima and colleagues, 1999Established
Ipamorelin releases GH selectively via a GHRP-like receptorRat cells, rats, swineRaun and colleagues, 1998Supported in animal models
The albumin-binding CJC-1295 persists in plasma and drives GH releaseRatsJetté and colleagues, 2005Supported for the DAC form
CJC-1295 sustains growth in a GHRH-deficient mouseKnockout mouse, 5 weeksAlba and colleagues, 2006Supported for the DAC form
The no-DAC analog is short-acting and pulse-likeStructure and animal-model description; limited primary kinetic dataPillar overviewReasoned, partly inferred
The two peptides combined give a different response from either alone in a given modelNo dedicated primary study in the references hereNoneInference; test with single-peptide arms

Receptor evidence: two inputs, one cell type

The GHRH receptor was cloned from rat pituitary and its human homolog expressed in human kidney 293 cells, where it bound GHRH with high affinity and raised cAMP (Mayo, 1992). The secretagogue receptor was identified as a receptor in pituitary and hypothalamus that functions in GH release (Howard and colleagues, 1996), and its natural ligand, ghrelin, was isolated from stomach as a GH-releasing acylated peptide (Kojima and colleagues, 1999). A review of the regulation of GH secretion by GH-releasing peptides and their mimetics sets out this second pathway alongside GHRH (Smith and colleagues, 1997). Convergence on one cell type is the rationale for pairing a GHRH analog with a secretagogue, and it is a rationale, not a measured interaction.

Ipamorelin evidence

Raun and colleagues (1998) described ipamorelin as a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) of high GH-releasing potency and efficacy in vitro and in vivo. In primary rat pituitary cells it released GH with potency and efficacy similar to GHRP-6; pharmacological profiling with GHRP and GHRH antagonists indicated that it acts through a GHRP-like receptor. In anaesthetized rats and conscious swine it released GH in dose-dependent fashion. In swine, none of the secretagogues tested affected FSH, LH, prolactin or TSH, and while GHRP-6 and GHRP-2 raised ACTH and cortisol, ipamorelin did not do so beyond levels seen after GHRH stimulation, even at doses over 200-fold above the ED50 for GH release. That selectivity is the main reason it is a reference secretagogue. Product details are on the ipamorelin page.

CJC-1295 evidence

The primary CJC-1295 papers concern the albumin-binding compound. Jetté and colleagues (2005) found a four-fold increase in GH area under the curve over two hours relative to hGRF(1-29) in rats and plasma presence beyond 72 hours. Alba and colleagues (2006) reported normal body weight and length in knockout mice with once-daily administration over five weeks, and increased pituitary GH mRNA. The no-DAC compound sold by V8 is the unconjugated modified fragment; claims about its behavior borrow from the shared backbone. For the form comparison see DAC versus no DAC and the CJC-1295 (No DAC) page.

Where the stack claim goes beyond the evidence

Statements such as “the two peptides act synergistically” are interactions. Demonstrating one needs a design in which the combined response is compared with each single-peptide response at matched concentrations, and ideally with an additivity model. None of the references in this article reports such a comparison. That does not mean the interaction is absent; it means a reader citing it should say what was and was not tested. Plan that comparison with single-peptide controls (the blend versus separate vials article discusses sourcing), and define the endpoint and sampling time in advance, since the axis is pulsatile and timing changes outcomes (Clark and Robinson, 1985).

Open questions a dedicated study could answer

Mapping the evidence also exposes the gaps. Four questions recur, each answerable with a design that is feasible at the bench.

  1. Is the combined response additive, greater or smaller than the sum of the parts? Single-peptide concentration–response curves for each peptide, plus a combined curve, allow an additivity analysis instead of an impression.
  2. Does the order or timing of exposure matter? Because the axis is pulsatile and the two peptides act through different receptors, simultaneous and staggered exposure are different experiments.
  3. Does the short-acting no-DAC analog behave like the better-characterized albumin-binding analog in the same assay? A paired comparison within one experiment answers this directly.
  4. How much does somatostatin tone limit the response? Adding somatostatin to the medium, or removing it, shows how much of the response ceiling is set by the inhibitory input.
Open questionMinimum design
AdditivityThree concentration–response series: each peptide alone and the pair at fixed ratio
TimingSimultaneous versus staggered exposure, same total exposure
Form comparisonNo-DAC and DAC analogs in one plate or cohort
Inhibitory tonePlus and minus somatostatin in the medium

How to cite the stack responsibly

  • Cite each peptide’s primary paper for what it showed, and say which form (DAC or no DAC) was studied.
  • Describe the pair’s rationale as receptor convergence, with the receptor papers as support.
  • Label any combined-response statement as a hypothesis unless your own data support it.
  • State vial size, lot and preparation method; the formula concentration = mass ÷ volume reproduces the arithmetic, and the calculator does it.
  • Keep certificate references, where published, from the COA library.

A broader coverage of paired and multi-peptide formats is in peptide blends and research stacks.

Frequently asked questions

What evidence supports a CJC-1295 + ipamorelin stack?

Separate literatures for each peptide, plus receptor papers showing that both pathways act on pituitary somatotrophs. No dedicated primary study of the pair is included in the references here.

Is the combined effect proven to be synergistic?

Not by the sources cited here. A synergy claim needs single-peptide arms and a matched-concentration comparison.

Which form of CJC-1295 do the primary papers study?

The albumin-binding DAC form. The no-DAC compound shares the backbone but has fewer dedicated primary studies.

Why is ipamorelin called selective?

In swine it did not raise ACTH or cortisol beyond levels seen after GHRH stimulation, even at doses over 200-fold above the ED50 for GH release, unlike GHRP-6 and GHRP-2 (Raun and colleagues, 1998).

What receptors do the two peptides act on?

CJC-1295 acts on the GHRH receptor; ipamorelin on the ghrelin receptor, which was identified as a receptor in pituitary and hypothalamus functioning in GH release.

What does “research stack” mean?

A catalog term for compounds often studied together. It describes common practice, not an established result.

How should the rationale be stated in a paper?

As receptor convergence on one cell type, citing the receptor papers, with the combined response described as a hypothesis unless the study tests it.

What controls does a stack experiment need?

Vehicle, CJC-1295 alone, ipamorelin alone, a positive control for each receptor, and a defined sampling schedule.

Is the blend equal in mass or moles?

Equal in mass (1:1). Ipamorelin is much smaller, so the blend has more ipamorelin molecules than CJC-1295 molecules.

Is this a guide for use outside the laboratory?

No. It maps published research. V8 supplies the products for laboratory research use only.

Related reading: CJC-1295 Ipamorelin Blend: Lab Planning Guide, CJC-1295 Ipamorelin Blend Shelf Life and Stability, CJC-1295 Ipamorelin Blend or Separate Vials?.

References

  1. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. doi:10.1210/mend.6.10.1333056
  2. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
  3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. doi:10.1038/45230
  4. Smith RG, Van der Ploeg LHT, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18(5):621-645. doi:10.1210/edrv.18.5.0316
  5. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
  6. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
  7. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
  8. Clark RG, Robinson ICAF. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature. 1985;314(6008):281-283. doi:10.1038/314281a0

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.